top of page

Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval

  • Jun 10, 2024
  • 1 min read

Updated: Jul 23, 2025

Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from Iovance, and discusses Replimune's plans to file for accelerated approval.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page